济南龟头敏感度要怎么治疗济南医院哪有男科,济南儿童切割包皮,济南30岁男人早泄能治疗好吗,济南尿等待是前列腺吗,济南阴虱是多长时间,济南治疗阳早射,济南男科医院治疗价格

The South Carolina Education Lottery reported on its website early Wednesday morning that one winning ticket was sold in its state.Mega Millions announced the win in a statement early Wednesday."The moment we've been waiting for finally arrived, and we couldn't be more excited," said Gordon Medenica, lead director of the Mega Millions Group and Director of Maryland Lottery and Gaming. "This is truly a historic occasion. We're so happy for the winner, and we know the South Carolina Education Lottery can't wait to meet the lucky ticket holder."The Mega Millions jackpot on Tuesday reached .573 billion, the game's largest-ever grand prize but not quite the nation's biggest prize of all time. A Powerball prize in 2016 was for .586 billion. The winning numbers on Tuesday were:28-70-5-62-65 and the Mega Ball was 5.Had a winning ticket not been sold on Tuesday, Friday's jackpot would have reached billion. Winning Tuesday's entire jackpot means either taking the .6 billion winnings in annuity payments spread over 29 years, or taking the lump sum of 3 million.  1112

The University of Washington’s Institute for Health Metrics and Evaluation has been issuing frequent projections since March in an attempt to model the spread and impact of the coronavirus across the world.The models have been used by the CDC and White House coronavirus task force in an effort to better understand the potential number of deaths the coronavirus could cause.On Friday, the model added a new variable, one that could cause a steep decline of coronavirus deaths throughout the US. The IHME’s newest model, which predicts the number of coronavirus deaths in the US through the end of March, is now weighing the potential impact of vaccines on the virus.For those hoping for an immediate drop in hospitalizations and deaths caused by the coronavirus as soon as vaccinations begin later this month might be disappointed. The IHME's model shows the initial batch of vaccinations will have a relatively muted effect on deaths and hospitalizations initially. While by April 1, much of the general US population will likely not be fully vaccinated, many in the high-risk category should expect to vaccinated by then. How fast they get vaccinated will play a role in determining the number of coronavirus deaths in the US.As of Friday evening, there have been over 278,000 coronavirus-related deaths reported throughout the US, per Johns Hopkins University data. Without any vaccines reaching Americans, the IHME’s model projects a total of 548,000 would die from the coronavirus through April 1, meaning 270,000 deaths between now and then.If COVID-19 vaccines are distributed at expected levels, 9,000 lives would be saved by April 1, reducing the number of deaths between now and then to 261,000. But a rapid vaccine rollout – one that would vaccinate the high-risk population and begin to vaccinate the general population by the spring -- would result in 250,000 deaths between now and April 1.“Mass scale-up of vaccination in 2021 means we have a path back to normal life, but there are still a few rough months ahead,” said Dr. Christopher Murray, IHME director. “We must be vigilant in protecting ourselves at least through April, when, as our projections indicate, vaccines will begin to have an impact.”In the meantime, Murray says universal mask wearing and social distancing will save more lives than a potential vaccine in the next four months.“Especially in the Northern Hemisphere, it’s crucial for governments to impose or re-impose mandates that limit gatherings and require masks. Where the winter surge is driving spikes in infections, there will be many people who can still become infected and possibly die before the vaccine is fully rolled out,” said Murray.To see the IHME’s state-by-state projections for deaths, hospitalizations and cases, clickhere. 2790

The University of Washington’s Institute for Health Metrics and Evaluation now projects that 33,000 American lives would be saved between now and October 1 by near universal wearing of masks.The IHME released the updated model on Wednesday.The IHME’s coronavirus projections have been frequently cited in the past by the White House’s coronavirus task force. The group uses state data along with other metrics to create projections on the number of coronavirus-related deaths throughout the US.The projection state that the US is currently on track to have an additional 58,000 coronavirus-related deaths between now and October 1. But that number drops to just 23,000 if masks are universally worn in public. Those figures are on top of the over 121,000 reported coronavirus-related deaths since the beginning of the pandemic.The IHME’s model projects that the US death toll will stay consistent on a per-day basis between now and September, before starting to increase in the fall. But the model projects that fewer than 100 Americans will die per day from coronavirus by September if masks are worn.The IHME’s latest model projects that coronavirus-related deaths will continue to surge in the states of Texas, Arizona and Florida in the coming weeks, while leveling or dropping off in many other states.To see a state-by-state breakdown of the IHME’s projections, click here.Last month, a study in the Lancet found that the use of masks and respirators by those infected with the virus reduced the risk of spreading the infection by 85%. The authors analyzed data that showed that N95 respirators in healthcare settings were up to 96% effective. Other masks were found to be 77% effective. 1701

The US Food and Drug Administration approved two cancer treatments, Vitrakvi and Xospata, this week after expedited reviews.Vitrakvi, approved Monday, is "a treatment for adult and pediatric patients whose cancers have a specific genetic feature (biomarker)."The FDA said in a statement that it is the second approved cancer treatment that is based on a tumor biomarker instead of the place in the body where the tumor originated.Vitrakvi will be used for the treatment of solid tumors that have an NTRK (neurotrophic receptor tyrosine kinase) gene fusion that do not have a known resistance mutation, that are not metastatic or where surgical removal is likely to lead to severe morbidity, and that have no alternative treatments or have progressed after treatments.NTRK genes are rare but occur in many types of cancer, the FDA said, such as mammary analogue secretory carcinoma and infantile fibrosarcoma.Xospata tablets, approved Wednesday, are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation," according to the FDA.Alongside the tablets, the agency also approved a diagnostic to detect the mutation."Approximately 25 to 30 percent of patients with AML have a mutation in the FLT3 gene. These mutations are associated with a particularly aggressive form of the disease and a higher risk of relapse," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in the statement.AML is a rapidly progressing cancer that affects the numbers of normal blood cells and calls for continuous transfusions, the FDA said.Both treatments were granted Priority Review designation.Priority Review, established in 1992, means the FDA aims to review the drug or treatment within six months, opposed to 10 months for a standard review."A Priority Review designation will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications," the FDA says.Both treatments also received?orphan drug?designation, a status granted to drugs for rare diseases or conditions. 2261

The U.S. Constitution states in order to be president, you must be 35 years of age, a natural born citizen, and must have lived in the United States for at least 14 years. To become vice president, you have to be eligible to become president.Sen. Kamala Harris, 55, was born in Oakland, California, in 1964 and a US citizen at birth. Akin to the controversy he tried to stir during the Barack Obama's Presidency, President Donald Trump suggested on Thursday that Harris isn’t eligible to run for vice president.Harris on Tuesday was announced as Joe Biden’s running mate on this year’s Democratic presidential ticket."I heard it today that she doesn't meet the requirements. And, by the way, the lawyer that wrote that piece is a very qualified, very talented lawyer,” Trump said.On Thursday, Newsweek published an op-ed questioning her eligibility. Newsweek defended the op-ed's publication. The argument that the op-ed makes, penned by John C. Eastman, is that Harris isn't a natural born citizen because her parents were not US citizens at the time of her birth. The issue Eastman raises is that the US constitution does not define "natural born citizen." But the 14th amendment clearly states that those born on US soil are citizens at birth."All persons born or naturalized in the United States, and subject to the jurisdiction thereof, are citizens of the United States and of the state wherein they reside," the amendment reads.Similar controversies have transpired when Sens. John McCain and Ted Cruz ran for president. Both were US citizens at birth, but were not born on US soil. Harris was born to two immigrant parents, a Jamaican father and Indian mother. According to his official college biography, Harris’ father Donald J. Harris was born a Jamaican citizen but has naturalized as an American citizen. Donald J. Harris is a professor emeritus at Stanford.According to her official obituary, the senator’s mother Shyamala Gopalan Harris, who died in 2009, came to the United States as a teenager and began participating in the Civil Rights Movement. She then became a cancer researcher at UC Berkeley. 2124